Biomarin Pharmaceutical IncBMRN

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$60.26
Market cap
$11.7B
P/E
159.8x
Revenue (TTM)
$3.4B
Net income
$73.0M
Dividend yield
—
1-year total return
14.5%
Net margin
2.1%
Revenue growth
11.2%
Debt / equity
0.66x

What Biomarin Pharmaceutical Inc does.

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.

In 2025, we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued to grow our commercial business and advance our product candidate pipeline. We believe that the combination of our internal research programs, partnerships and acquisitions of external assets will allow us to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions. We periodically conduct strategic portfolio assessments of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders. Based on such strategic portfolio assessments, certain programs that do not meet our threshold for further development and commercialization could be discontinued.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$1.9B$1.8B$2.1B$2.4B$2.9B$3.2B
Net income$854.0M-$64.1M$141.6M$167.6M$426.9M$348.9M
Free cash flow-$28.9M$209.0M$54.9M$62.6M$487.4M$725.0M

More on BMRN.

Figures from Biomarin Pharmaceutical Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.